647 related articles for article (PubMed ID: 33549048)
21. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
22. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
23. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
25. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
[TBL] [Abstract][Full Text] [Related]
26. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
27. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
28. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
29. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
31. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
32. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Villanueva J; Vultur A; Lee JT; Somasundaram R; Fukunaga-Kalabis M; Cipolla AK; Wubbenhorst B; Xu X; Gimotty PA; Kee D; Santiago-Walker AE; Letrero R; D'Andrea K; Pushparajan A; Hayden JE; Brown KD; Laquerre S; McArthur GA; Sosman JA; Nathanson KL; Herlyn M
Cancer Cell; 2010 Dec; 18(6):683-95. PubMed ID: 21156289
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Byron SA; Loch DC; Wellens CL; Wortmann A; Wu J; Wang J; Nomoto K; Pollock PM
Mol Cancer; 2012 Oct; 11():75. PubMed ID: 23039341
[TBL] [Abstract][Full Text] [Related]
34. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
35. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
36. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
38. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
Van Dort ME; Jang Y; Bonham CA; Heist K; Palagama DSW; McDonald L; Zhang EZ; Chenevert TL; Luker GD; Ross BD
Eur J Med Chem; 2022 Feb; 229():113996. PubMed ID: 34802837
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Shi H; Hugo W; Kong X; Hong A; Koya RC; Moriceau G; Chodon T; Guo R; Johnson DB; Dahlman KB; Kelley MC; Kefford RF; Chmielowski B; Glaspy JA; Sosman JA; van Baren N; Long GV; Ribas A; Lo RS
Cancer Discov; 2014 Jan; 4(1):80-93. PubMed ID: 24265155
[TBL] [Abstract][Full Text] [Related]
40. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
